Abstract
ABSTRACT - BACKGROUND:Ductal adenocarcinoma of the pancreas is the fourth most common cancer-associated cause of death in the Western world. The presence of circulating tumor cells (CTCs) can be considered a potential prognostic factor, as these cells represent tumor progression, allowing monitoring of therapeutic efficacy.OBJECTIVES: The objectives of this study were to explore the morphological, molecular, and phenotypic characteristics of CTCs from the blood of patients with pancreatic carcinoma and to correlate the findings with response to treatment, progression-free survival, overall survival (OS), and deep vein thrombosis (DVT).METHODS: Peripheral blood (10 mL) was analyzed before the beginning of treatment after 60 and 120 days. CTCs were detected by using ISET® and characterized by immunocytochemistry. For microRNAs (miRNAs) analysis, peripheral leukocytes from the same patients and healthy individuals (controls) were collected in parallel at baseline. The expression of miRNAs was evaluated (in pool) using TaqMan® Array Human MicroRNA Cards v2.0.RESULTS: Only nine patients were included. The proteins, namely, matrix metalloproteinase-2 (MMP2) and TGFβ-RI, were highly expressed (77.7%) in CTCs at baseline; at the first follow-up, MMP2 was predominant (80%) and, at the second follow-up, MMP2 and vimentin were predominant (50%). Circulating tumor microemboli (CTMs) were found in two patients and both presented DVT. The miR-203a-3p was highly expressed in CTCs. The miR-203a-3p is involved in the stimulation of epithelial-to-mesenchymal transition (EMT) and is related to worse OS in pancreatic cancer (TCGA data).CONCLUSION: Due to the low number of patients and short follow-up, we did not observe a correlation between CTCs and response to treatment. However, there was a correlation between CTM and DVT and also miR-203a-3p was highly expressed in CTCs, corroborating the findings of EMT proteins. This study opens the perspectives concerning the dynamic change in the pattern of proteins expressed along with treatment and the use of miRNAs as new targets in pancreatic carcinoma.
Highlights
EHsoowpehvaegr,etahleraenwdags aasctorricrevlaatiroicnebse.tween CTM and DVT and miR-203a-3p was highly expressed in células tumorais circulantes (CTCs), corroborating the findings of epithelial-to-mesenchymal transition (EMT) proteins
This study opens the perspectives concerning the dynamic change in the pattern of proteins expressed along with treatment and the use of miRNAs as new targets in pancreatic carcinoma
Coionrmfgluo/e1cn0ict.a1iar5ea9s0sve/a0rai1art0çiãg2oo-6:dd7oe20Bca2ial0isbe2r1eS0ildv0aa0s-2Nveea1troi6z2eWs8Be, QasuitraexsaesCd, eDereMssoanugraraEmGHen, tCooenlahoesFqFu, HisteormssoanmPo.sAe qnuoesdeagduaimperenstsoãoempolrotanlgaopópsradzeos?vaAsBcCulDariAzarqçãBoraessoCfairgDogigá.s2tr0ic2a1;e34e(s2p)l:een15e8ct1o.mDiOaI: in/f1lu0e.1n5c9ia0/a01v0a2ri-a6ç7ã2o0d2o02c1a0li0b0r1eed1a5s81varizes e as taxas de ressangramento na esquistossomose no seguimento em longo prazo? ABCD Arq Bras Cir Dig. 2021;34(2):e1581
Summary
Ocâncer de pâncreas é atualmente classificado como o 14o câncer mais comum e a 7a principal causa de mortalidade por câncer no mundo. Os critérios de inclusão foram: pacientes com diagnóstico histológico de carcinoma pancreático localmente avançado ou metastático; pacientes com mais de 18 anos; pacientes submetidos à primeira linha de tratamento; doença metastática confirmada por avaliação patológica e / ou radiológica; extensão da doença determinada por exame clínico e imagem; doença mensurável pelos critérios RECIST versão 1.1 (Critérios de Avaliação de Resposta em Tumores Sólidos). Após 10 minutos de homogeneização, as amostras foram depositadas em ISET BlockTM, que contém uma membrana de policarbonato com poros circulares de 8 μm de diâmetro. Os resultados foram dados em número de CTCs por ml de sangue, de acordo com a análise estatística realizada por Krebs et al (2012),[12] contando CTCs em 4 pontos de membrana ou mais. A presença e ausência de MTCs foi incluída na análise
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
